

Issued: 17 April 2026

Viral Vector Manufacturing Facility (VVMF) to attend ARM's Cell and Gene Meeting on the Med 2026

Viral Vector Manufacturing Facility Pty Ltd (VVMF) today announced its participation in **ARM's Cell and Gene Meeting on the Med 2026**, taking place **28 – 30 April 2026, in Rome, Italy**.

Anita van der Meer, Head of Business Development and Partnerships at VVMF, will be available to discuss the organisation's expertise across research, process and analytical development, GMP viral vector manufacturing, and the wrap-around services to leverage the advantages of the Australian biotechnology ecosystem.

As Australia's only viral vector Contract Development and Manufacturing Organisation (CDMO) providing complete life cycle services to the global cell and gene therapy (CGT) sector, VVMF delivers high-quality **lentiviral (LV) and adeno-associated viral (AAV) vector solutions** tailored to their **research, clinical, and commercial needs**.

Backed by leading scientific and clinical expertise, VVMF provides a compelling strategic advantage - further strengthened by Australia's 43.5% R&D tax incentive, which provides **a rebate of up to 43.5% for eligible companies**.

Commenting on VVMF's participation, Anita van der Meer said:



"With its strong international focus, ARM's Cell & Gene Meeting on the Med provides an ideal platform to engage with innovators shaping the future of cell and gene therapy. I look forward to discussing how VVMF's capabilities, and the Australia Advantage, can support the progression of advanced therapies."

To schedule a meeting, connect via the meeting's **PartneringONE™ platform** or contact info@vvmf.com.au

Unlocking the future of medicine – through strong connections built at ARM's Cell and Gene Meeting on the Med.

End -

About VVMF – Unlocking the Future of Medicine

Viral Vector Manufacturing Facility Pty. Ltd. (VVMF) is Australia's only Contract Development and Manufacturing Organisation (CDMO) dedicated to providing services in the research, design, development, and manufacture of viral vectors for advanced therapeutic applications. VVMF partners with researchers, clinicians, and biopharma companies to accelerate the path to market for cell and gene therapies to local and global patients.

Viral vectors play a crucial role in delivering genetic material into cells and are central to innovative treatments in areas of medicine including cancers and rare diseases.

Contact - For further information please contact media@vvmf.com.au

[1] **Postal address:** Viral Vector Manufacturing Pty Ltd, PO BOX 287, Westmead NSW 2145. ABN 20675249546

Address: Viral Vector Manufacturing Facility Pty Ltd, Level 4, Kids Research, The Children's Hospital at Westmead, 178 Hawkesbury Road, Westmead, NSW, 2145